A Phase 1b/2a Randomized Open-label Study Measuring Chyme Concentrations of Intravenously Administered Ceftriaxone in the Presence of the Oral Beta-lactamase SYN-004

Marianne Ruflange, Ph.D., FPMP, Sylvie Bolly R.T., Eric Sicard, M.D., Marc Lefebvre, Ph.D.; Algorithme Pharma Inc., Montreal, Canada
Tracey Roberts, Heidi Whalen, Olivia Coughlin, Ph.D., John Kokal-Kun, Ph.D. and Joseph Sliman M.D., MPH.; Synthetic Biologics, Inc., Rockville, MD, USA

Background and Purpose
SYN-004 is an oral recombinant β-lactamase developed by Synthetic Biologics, Inc., and intended to degrade certain intravenous (IV) β-lactam antibiotics excreted into the gut, thereby mitigating their compromising effects on the gut microbiome, and correspondingly preventing opportunistic hospital-acquired, bacterial infections such as C. difficile.

In the U.S., the White House issued a National Action Plan for combating antibiotic-resistant infections including C. difficile infection (CDI) in March 2015 with the aim of reducing the incidence of CDI by 50% by 2020.

Methods
Nine otherwise healthy subjects with functioning ileostomies (see Figure 1) were enrolled at Algorithme Pharma Inc., a Phase 1 Clinical Research Organization based in Montreal, Canada. Seven male patients were aged between 24 and 74 years old, and two female patients were respectively of 53 and 60 years old.

In the first treatment period, all subjects received an infusion of ceftriaxone and, in the second treatment period, were randomized to receive one of the two single oral doses of SYN-004 (75 or 150 mg) twice in one day (early morning and early afternoon), with a single IV dose of 1g ceftriaxone, 30 minutes following the first dose of SYN-004 (see Figure 3). Subjects were confined in the clinical unit for 24 hours, and medical monitoring lasted one week after the end of the second confinement period. PK sampling was up to 8.5 hours post-dose during Treatment Period 1 and Treatment Period 2, both in plasma and chyme. The uniqueness of this study design resides in the special population that are patients with ileostomies. The presence of the ileostomy permits access to the chyme in the small intestine.

The purpose of this study was to evaluate the ability of SYN-004 to degrade ceftriaxone secreted into the small intestine after IV administration without affecting antibiotic pharmacokinetics (PK) in the bloodstream.

Results
To successfully enrol nine patients over a period of seven months (see Figure 2), Algorithme Pharma’s recruitment team had a total of 105 prescreen phone conversations with prospective volunteers with ileostomy, and 52 screening appointments were completed. Main reasons for screening failure were concurrent medical conditions, safety laboratory parameters out of range, and use of prohibited medications.

Table 1 shows that the 75 and 150 mg single doses of SYN-004 as well as the single dose of ceftriaxone were very well tolerated. AEs were mostly mild to moderate in intensity and all patients had recovered from their AEs at the end of their study participation.

The uniqueness of this study design resides in the special population that are patients with ileostomies. The presence of the ileostomy permits access to the chyme in the small intestine.

Conclusions
The clinical portion of this Phase 1b/2a study was successfully completed. The methodology used in this trial of sequential sampling and analyzing the chyme should prove to be a powerful approach to allow the direct measurement of the degradation of ceftriaxone in the small intestine.

Acknowledgements
Authors would like to give special thanks to their team in recruitment and screening for their exceptional work on this study: Marie Sissoko, Sandrine Lan Hing Wai, Helen Paraskevopoulos, and Petra Hillebrand.